共 38 条
- [1] Characterization of APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, in preclinical models of AML and nonhuman primatesMOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)Comeau, Michael R.Miller, Robert E.Bannink, JeannetteJohnson, StarrlaBader, RobertGottschalk, RebeccaMisher, LyndaMitchell, DanielleParr, LaraDeFrancesco, MelissaBienvenue, DavidMcMahan, Catherine J.Hoyos, Gabriela H.Gross, Jane A.
- [2] Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir T Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromeBLOOD, 2022, 140 : 6204 - 6205Watts, JustinMaris, MichaelLin, Tara L.Patel, PraptiMadanat, Yazan F.Cogle, Christopher R.Borthakur, GautamHuebner, DirkKhaskhely, NoorBonham, LynnMassaro, MonicaTaylor, DaphneTaromino, CarolineMims, Alice S.
- [3] APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR® molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine releaseCANCER RESEARCH, 2018, 78 (13)Comeau, Michael R.Miller, Robert E.Bader, RobertGottschalk, RebeccaDaugherty, MollieSewell, ToddyMisher, LyndaParr, LaraDeFrancesco, MelissaBienvenue, DavidMcMahan, Catherine J.Hoyos, Gabriela H.Gross, Jane A.
- [4] APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity with limited cytokine release, is well tolerated in repeat dose toxicology studies in cynomolgus macaquesCANCER RESEARCH, 2019, 79 (13)Comeau, Michael R.Gottschalk, RebeccaDaugherty, MollieSewell, ToddyMisher, LyndaJeannette, BanninkJohnson, StarrlaParr, LaraKumer, JohnJablonski, DavidDeFrancesco, MelissaBienvenue, DavidHoyos, Gabriela H.McMahan, Catherine J.Gross, Jane A.
- [5] Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromeBLOOD, 2020, 136Watts, Justin M.Lin, TaraWang, Eunice S.Mims, Alice S.Cull, Elizabeth H.Patel, Prapti A.Shami, Paul J.Walter, Roland B.Cogle, Christopher R.Chenault, Ruth A.Macpherson, BretChunyk, Allison GivenMcMahan, Catherine J.Gross, Jane A.Stromatt, Scott
- [6] Bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecules for redirected T-cell cytotoxicity in hematological malignanciesCANCER RESEARCH, 2017, 77Comeau, Michael R.Mitchell, DanielleGottschalk, RebeccaMisher, LyndaDaugherty, MollieParr, LaraPavlik, PeterWoodruff, BrianFang, HangAguilar, MeganBannink, JeannetteJohnson, StarrlaLi, GaryMiller, Robert E.Bader, RobertZhang, NicoleSewell, ToddyDasovich, MariaHoyos, Gabriela H.Blankenship, John W.McMahan, CatherineBienvenue, DavidGross, Jane A.
- [7] Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDSBLOOD, 2021, 138Watts, Justin M.Lin, Tara L.Mims, Alice S.Patel, PraptiShami, Paul J.Cull, Elizabeth H.Cogle, Christopher R.Lee, CynthiaUckun, Fatih
- [8] Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436CANCERS, 2021, 13 (21)Uckun, Fatih M.Watts, JustinMims, Alice S.Patel, PraptiWang, EuniceShami, Paul J.Cull, ElizabethLee, CynthiaCogle, Christopher R.Lin, Tara L.
- [9] Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436BLOOD, 2021, 138Lim, Tara L.Watts, Justn M.Mims, Alice S.Patel, PraptiShami, Paul J.Cull, Elizabeth H.Cogle, Christopher R.Lee, CynthiaUckun, Faith
- [10] Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMAFRONTIERS IN ONCOLOGY, 2022, 11Watts, JustinLin, Tara L.Mims, AlicePatel, PraptiLee, CynthiaShahidzadeh, AnoushShami, PaulCull, ElizabethCogle, Christopher R.Wang, EuniceUckun, Fatih M.